Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Orgenesis is a vertically-integrated biopharmaceutical company with unique experti...
Orgenesis is a vertically-integrated biopharmac...
Guardion Health Sciences is at the forefront of early detection, intervention and ...
Guardion Health Sciences is at the forefront of...
Curis is a biotechnology company focused on the development and commercialization ...
Curis is a biotechnology company focused on the...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...
Takeda Pharmaceutical Company Limited (TSE:4502...
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company fo...
Portola Pharmaceuticals is a global, commercial...
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...
Rigel Pharmaceuticals, Inc. is a biotechnology ...
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on ...
Karyopharm Therapeutics is an innovation-driven...
20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...
20/20 GeneSystems, Inc. an early stage digital ...
Join the National Investor Network and get the latest information with your interests in mind.